Insights into New Myeloma Tx: Revlimid Study Tops List of Investigations that may Benefit Patients
By Ruben Niesvizky, MD
Recently, the Myeloma Program at New York-Presbyterian Hospital/Weill Cornell Medical Center has generated a considerable amount of excitement by launching a study evaluating a combination regimen, known as BiRD, that includes the antibiotic Biaxin&r
Be the first to comment